Background: We sought to evaluate the impact of adjuvant chemotherapy on overall survival (OS) in patients with stage I endometrioid epithelial ovarian cancer (EEOC) or ovarian clear cell cancer (OCCC) using a national database.
Introduction
Epithelial ovarian cancer (EOC) is a collective term for all histologic entities that historically were thought to originate from ovarian epithelium. Studies suggest that the majority of high-grade serous carcinomas (HGSCs) arise in the fallopian tube, whereas endometrioid and clear cell ovarian carcinomas likely arise from ovarian or pelvic endometriosis [1] . The classification as EOC insufficiently accounts for the distinct clinical, pathologic, and biological features among these cancers.
Endometrioid EOCs (EEOCs) comprise 5%-10% of all EOCs, are frequently low grade, are typically diagnosed at an earlier stage, and are believed to be associated with a better prognosis compared with other histologic subtypes [1, 2] . Recent gene profiling studies have suggested that low-grade EEOC is distinct from high-grade EEOC [3] . Current guidelines of the National Comprehensive Cancer Network (NCCN) recommend observation for patients with substage IA or IB, grade 1 EEOC [4] . Adjuvant chemotherapy is optional for patients with substage IA or IB, grade 2 or 3 disease and is recommended for patients with substage IC disease of any grade.
Similar to EEOC, ovarian clear cell carcinoma (OCCC) is a rare histologic subtype that accounts for 5%-10% of all EOCs and is distinct with regard to clinical behavior and tumor biology compared with HGSC. OCCC also is more commonly diagnosed at a younger age and has a higher prevalence among Asians [5] . Patients presenting with advanced OCCC show limited response to platinum-based chemotherapy and have lower 5-year survival rates compared with patients with HGSC [6] . Despite a lack of convincing data, the NCCN recommends chemotherapy for all patients with early-stage OCCC [4] .
Data from prospective studies evaluating the efficacy of adjuvant chemotherapy are mainly derived from patients with HGSC. Given the lack of prospective data regarding the benefit of adjuvant chemotherapy in early-stage EEOC and OCCC, we used information from a national database to evaluate the impact of adjuvant chemotherapy on overall survival (OS) in patients with stage I EEOC or OCCC [7] .
Methods

Data source
The Surveillance, Epidemiology, and End Results (SEER) database was used for analysis. SEER is a population-based cancer registry maintained by the National Cancer Institute. The database 'SEER 18 Regs Custom Data with chemotherapy recode, November 2015 (2000-2013) <Katrina/Rita Population Adjustment>' was searched for '8.5.3 Carcinoma of Gonads', 'Malignant', and 'C56.9-Ovary'. Our search yielded 70 702 patients with recorded chemotherapy and American Joint Committee on Cancer (AJCC) staging status for the years 2000-2013 [7] .
Study population
The following variables were exported from SEER*Stat 8.3.2 software to Microsoft Excel for further analysis: age at diagnosis, race, tumor stage, tumor grade, year of diagnosis, lymph node (LN) dissection, radiation therapy, surgery at primary site, and whether or not chemotherapy was administered. For EEOC, patients with the following ICD-O-3 histologies were selected: 8380/3: endometrioid carcinoma; 8381/3: endometrioid adenofibroma, malignant; 8382/3: endometrioid adenocarcinoma, secretory variant; and 8383/3: endometrioid adenocarcinoma, ciliated cell variant. For OCCC, patients with the following ICD-O-3 histologies were selected: 8310/3: clear cell adenocarcinoma, NOS; 8313/3: clear cell adenocarcinofibroma; 8443/3: clear cell cystadenocarcinoma; and 8444/ 3: clear cell cystic tumor, malignant.
Patients with stage II-IV disease or disease of unknown substage were excluded. All OCCCs were considered high grade [8, 9] . Patients who had undergone radiation therapy in the adjuvant setting or did not undergo surgery were excluded. A total of 3552 patients with stage I EEOC and 1995 patients with stage I OCCC were selected for further analysis (Figure 1 ).
Statistical analysis
Patient characteristics were compared using a v 2 test, and predictors of chemotherapy use were determined by binary logistic regression. Survival analysis was assessed with the Kaplan-Meier method, and the results were compared with the log-rank test. A Cox proportional hazards model was applied for multivariate survival analysis. P 0.05 was regarded as statistically significant. All statistical analyses were carried out with IBM SPSS 24.0.0.0.
Results
Patient demographics
We identified 3552 patients with International Federation of Gynecology and Obstetrics (FIGO) stage I EEOC (Table 1) . Overall, 1600 patients (45%) were treated with adjuvant chemotherapy; 2674 patients (75%) had at least one LN resected.
A total of 1995 patients with FIGO stage I OCCC were identified ( Predictors for receiving chemotherapy Table 1 lists associations between clinicopathologic variables and chemotherapy administration. Patients who underwent chemotherapy for EEOC were younger (P < 0.001) and had tumors of higher grade (P < 0.001) and stage (P < 0.001). Patients who underwent LN assessment were more likely to be treated with chemotherapy (79% versus 73%; P < 0.001 Patients with OCCC who underwent chemotherapy were younger (P ¼ 0.005), and had disease of higher substage (P < 0.001). Patients who underwent LN assessment were more likely to be treated with chemotherapy (P < 0.001). On multivariate analysis, younger age at diagnosis (OR 0.984; 95% CI: 0.975-0.992; P < 0.001), substage IC disease (OR 1.734; 95% CI: 1.415-2.125; P < 0.001), and more recent year of diagnosis (OR 1.046; 95% CI: 1.021-1.072; P < 0.001) were independently associated with adjuvant chemotherapy treatment (supplemen tary Table S1 , available at Annals of Oncology online).
Overall survival
The median follow-up for the surviving patients with EEOC was 65 months (range, 0-167 months; 95% CI: 66-72). The 5-year OS rate for all patients diagnosed with FIGO stage I EEOC was 90% (SE 0.6%). The 5-year OS rates were 90% (SE 0.7%) for patients with stage IA disease, 89% (SE 2.5%) for patients with stage IB disease, and 89% (SE 1.0%) for patients with stage IC disease (P ¼ 0.162; Figure 2A ). Higher tumor grade was associated with inferior OS. Patients with grade 1 and grade 2 EEOC had 5-year OS rates of 93% (SE 0.8%) and 90% (SE 0.9%), respectively; patients with grade 3 EEOC had a 5-year OS rate of 82% (SE 1.7%) (P < 0.001; Figure 2B ). The 5-year OS rates for patients who did and did not receive adjuvant chemotherapy were 90% (SE 0.9%) and 89% (SE 0.8%), respectively (P ¼ 0.807, Figure 2C ). On multivariate survival analysis (Table 2) , FIGO stage IC (HR 1.325; 95% CI: 1.085-1.618; P ¼ 0.006), grade 3 (HR 1.798; 95% CI: 1.407-2.296; P < 0.001), race (African American: HR 1.526; 95% CI: 1.038-2.243; P ¼ 0.032), and older age (HR 1.052; 95% CI: 1.044-1.059; P < 0.001) were associated with inferior OS. Administration of adjuvant chemotherapy (HR 0.996; 95% CI: 0.818-1.214; P ¼ 0.972) and LN assessment (HR 0.649; 95% CI: 0.401-1.049; P ¼ 0.077) were not associated with improved OS. A subgroup analysis of substages and grades was performed. On univariate analysis ( Figure 2D ), chemotherapy use was not associated with a survival benefit in patients with substage IA (n ¼ 2062) or IB (n ¼ 209) EEOC of any grade, or in patients with substage IC, grade 1 (n ¼ 441) or grade 2 (n ¼ 557) disease. A significantly longer 5-year OS rate of 81% was observed in patients with stage IC, grade 3 disease (n ¼ 283) who received chemotherapy compared with 62% in patients who did not (P ¼ 0.003). A multivariate analysis, including the variables of age at diagnosis, year of diagnosis, race, LN dissection, number of dissected LNs, and chemotherapy administration, was performed individually for each subgroup (supplementary Figure S1 , available at Annals of Oncology online). In the subgroup of patients with substage IC, grade 3 EEOC, adjuvant chemotherapy was associated with improved OS (HR 0.583; 95% CI: 0.359-0.949; P ¼ 0.030). We used the extent of LN dissection as a surrogate marker for completeness of surgical staging and evaluated the impact of adjuvant chemotherapy. In patients who had >10 or 1-10 LNs dissected, there was no association between chemotherapy administration and improved OS (supplementary Tables S2  and S3 , available at Annals of Oncology online). Only in un-staged patients with stage IC, grade 3 EEOC was chemotherapy associated with an improved 5-year OS rate (80% versus 43%; P ¼ 0.004; supplementary Table S4 , available at Annals of Oncology online).
In patients with OCCC, the median follow-up of the surviving patients was 64 months (mean 71.1; 95% CI: 86.8-73.4). The 5-year OS rate for all patients with FIGO stage I OCCC was 84% (SE 0.9%). The 5-year OS rates were 86% (SE 1.1%) for patients with FIGO stage IA/B disease and 82% (SE 1.6%) for patients with FIGO stage IC disease (P ¼ 0.025; Figure 3A ). The 5-year OS rates were 83% (SE 1.6%) for patients who did not undergo adjuvant chemotherapy and 85% (SE 1.1%) for those who did (P ¼ 0.434, Figure 3B ). Table 1 . Patient demographics of selected study cohort and association between patient characteristics and adjuvant chemotherapy Chemotherapy was not associated with improved OS when analyzed by stage; the 5-year OS rate was 87% (SE 1.4%) for patients with stage IA/B disease who underwent chemotherapy compared with 84% (SE 1.9%) for those who did not (P ¼ 0.308; Figure 3C ). For patients with stage IC disease, the 5-year OS rates were 83% (SE 1.8%) with chemotherapy compared with 80% (SE 3.3%) without (P ¼ 0.620; Figure 3D ).
Annals of Oncology
On multivariate analysis (Table 2) , only age at diagnosis (HR 1.038; 95% CI: 1.029-1.048; P < 0.001) and stage IC disease (HR 1.353; 95% CI: 1.080-1.694; P ¼ 0.009) were independently associated with OS. The use of adjuvant chemotherapy was not associated with improved OS (HR 1.013; 95% CI: 0.802-1.281; P ¼ 0.912). In a multivariate subgroup analysis, chemotherapy was not associated with OS in patients with stage IA/B or stage IC OCCC (supplementary Figure S1 , available at Annals of Oncology online). There was no association between chemotherapy administration and improved OS with >10 or 1-10 LNs dissected (sup  plementary Tables S5-S7 , available at Annals of Oncology online). Cox-regression; P 0.05 is regarded as statistically significant HR >1 is associated with worse overall survival (OS); HR <1 is associated with improved OS.
In the group of patients who did not undergo an LN dissection, there was also no detectable association between chemotherapy and OS (HR: 1.081; 95% CI: 0.719-1.623; P ¼ 0.709) (supplemen tary Tables S6, available at Annals of Oncology online). For more details regarding the impact of staging on efficacy of chemotherapy please see supplementary Materials section, available at Annals of Oncology online.
Discussion
In this study, we analyzed SEER data to evaluate the impact of adjuvant chemotherapy on OS in patients with early-stage EEOC or OCCC. Current treatment recommendations for all subtypes of ovarian cancer are based on data collected in cohorts dominated by the HGSC subtype. Two sentinel, randomized trials in early-stage ovarian cancer showed a benefit of adjuvant chemotherapy in FIGO stage I ovarian cancer regardless of tumor histology [10, 11] . Our analysis revealed that adjuvant chemotherapy had no impact on patient survival in the total cohorts of patients with EEOC and OCCC. Only patients with FIGO stage IC, grade 3 EEOC had an improved OS with the addition of chemotherapy, with a 5-year OS rate of 81% in patients who underwent adjuvant chemotherapy compared with 62% in those who did not. Grade 3 disease was associated with decreased OS, which is consistent with immunophenotypic and gene profiling studies that suggest high-grade EEOC is a subtype of HGSC [3] . In stage I OCCC, chemotherapy showed no association with OS, regardless of substage.
The retrospective nature and lack of randomization in our analysis does not account for selection bias or reasons for allocation of patients to treatment or observation. Additionally, in contrast to prospective trials, cases extracted from the SEER database were not revised by centralized pathology and are possibly prone to misclassification in less-specialized centers. Nevertheless, the large number of patients is a major strength of this study-1600 patients (45%) who received adjuvant chemotherapy for EEOC and 1952 who were observed (55%), which allowed for statistically meaningful analyses. This study includes the largest cohort of patients with stage I OCCC-1346 patients (67%) who underwent chemotherapy and 649 who did not (33%).
Gynecologic Oncology Group (GOG) study 157 evaluated the impact of 3 versus 6 cycles of adjuvant chemotherapy in earlystage EOC. In the subset of 105 patients with EEOC, there was no association between number of cycles and risk of disease recurrence, in contrast to HGSC patients who benefited from 6 cycles of chemotherapy [12] , suggesting limited efficacy of chemotherapy in stage I EEOC. In a retrospective study of patients treated at a center of the British Columbia Cancer Agency, Kumar et al. reported on the impact of adjuvant chemotherapy and radiation Annals of Oncology therapy in stage I/II EEOC. Their data showed no difference in disease-free survival between any type of treatment or observation in FIGO substage IA/B or IC disease due to tumor rupture [13] . In the SEER dataset, radiation therapy was documented in only 101 of the 3661 stage I EEOC patients, and therefore, patients treated with radiation therapy were excluded from our analysis.
In patients with OCCC, GOG 157 [14] showed no association between risk of recurrence and number of chemotherapy cycles [12] , questioning the efficacy of adjuvant chemotherapy in earlystage OCCC. This was supported in a recent retrospective analysis at 5 institutions, which showed no difference in recurrence and survival for patients who underwent either 3 or 6 cycles of adjuvant chemotherapy [15] . Other retrospective single or multicenter studies are limited by relative small sample sizes and report high rates of chemotherapy administration (>90%) [16] [17] [18] .
A weakness of our analysis is the limited information regarding treatment regimens and number of cycles, as well as uncertainties regarding the completeness of chemotherapy data in the SEER database. The chemotherapy variable provided by SEER is limited to two categories: 'chemotherapy yes' and 'no chemotherapy/ unknown'. A recently published comparison of the SEER registry with Medicare claims [18] reported a 94.7% positive predictive value for the chemotherapy variable in ovarian cancer, with a sensitivity of 84.4%. Consequently, 15% of the patients in the observation group might have received chemotherapy that possibly improved their survival. Although this bias cannot be ruled out, among patients who had chemotherapy recorded, 94.7% can be expected to have undergone adjuvant chemotherapy. Also, as we evaluated patients treated between the years 2000 and 2013, it can be presumed that a high proportion of patients in our analysis underwent platinum-and taxane-based therapy.
An additional limitation of our SEER database analysis is that we cannot distinguish whether FIGO stage IC refers to ovarian surface involvement or intraoperative cystic rupture. Some studies suggest that patients diagnosed with stage IC OCCC due to intraoperative rupture have a similar OS compared with that of patients with stage IA disease [16, 17] while surface involvement results in a significantly impaired OS. Also, both OCCC and EEOC are frequently associated with endometriosis [19] . Whether the early-stage OCCCs and EEOCs in our database were associated with endometriosis cannot be evaluated. This is important, as there is evidence that patients with carcinomas arising in endometriosis appear to have better survival outcomes than those without endometriosis [20] .
We were unable to access the impact of molecular markers on the efficacy of chemotherapy in this dataset. Microsatellite instability and mismatch-repair gene mutations with unique clinical and molecular features [21] [22] [23] [24] are well described for OCCC, while TP53 mutations are found in only 15% of OCCC cases compared with 96% of HGSC cases [25] . Mutations in ARID1A [26] and PIK3CA [27] , which are not found in HGSC, have been implicated in the early transformation of endometriosis to OCCC. Similarly, there are a lack of data regarding whether EEOC patients were tested for Lynch syndrome, which may have prognostic implications [28, 29] .
Only 41% of the patients with EEOC and 45% with OCCC had >10 LNs removed; consequently, a large proportion of our cohort did not undergo a comprehensive staging procedure.
We evaluated the impact of chemotherapy using the extent of LN dissection as a surrogate marker for completeness of surgery. The association of chemotherapy and improved OS was pronounced in patients with substage IC, grade 3 EEOC who did not undergo any LN evaluation. We hypothesize that this effect can be attributed to occult LN metastasis in patients with inadequate staging. Comprehensive systematic lymphadenectomy on the other hand likely resulted in a stage migration of patients with occult microscopic LN disease and a smaller effect of adjuvant chemotherapy in patients with EEOC and OCCC.
Clinical trials targeting patients with rare histologic subtypes of EOC, such as EEOC and OCCC, are warranted. Such trials can focus on the discovery of new biomarkers to predict individual response to standard chemotherapy and to determine actionable mutations for novel targeted agents [30] .
